BackParabilis Medicines Overview
Parabilis Medicines, Inc.

Parabilis Medicines Target Price

Analysts' average 12-month price target for Parabilis Medicines is $40.

Get informed when a big investor buys or sells

+ Follow

Share Price

$36.88

Average Target Price

$40.008.5% upside

2 analysts in the last 4 months

High: $40 | Low: $40

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-06Leerink Partners$408.5% upsideOpen
2026-07-06Guggenheim$408.5% upsideOpen

Parabilis Medicines (PBLS) FAQ

As of the most recent data, PBLS shows a target price of $40. Scroll down for historical charts and peer comparison views.

If Parabilis Medicines moved to the average analyst target of $40, shares would be roughly 8.5% higher than $36.88. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Parabilis Medicines's earnings trajectory.

Besides this target price page, Stockcircle has Parabilis Medicines's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $40) with ownership activity and broader fundamentals.

Parabilis Medicines's target price is $40; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.